Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS

To analyze the changes induced by ocrelizumab in blood immune cells of patients with primary progressive MS (PPMS). In this multicenter prospective study including 53 patients with PPMS who initiated ocrelizumab treatment, we determined effector, memory, and regulatory cells by flow cytometry at bas...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurology : neuroimmunology & neuroinflammation 2021-03, Vol.8 (2)
Hauptverfasser:	Fernández-Velasco, José I., Kuhle, Jens, Monreal, Enric, Meca-Lallana, Virginia, Meca-Lallana, José, Izquierdo, Guillermo, Gascón-Giménez, Francisco, Sainz de la Maza, Susana, Walo-Delgado, Paulette E., Maceski, Aleksandra, Rodríguez-Martín, Eulalia, Roldán, Ernesto, Villarrubia, Noelia, Saiz, Albert, Blanco, Yolanda, Sánchez, Pedro, Carreón-Guarnizo, Ester, Aladro, Yolanda, Brieva, Luis, Íñiguez, Cristina, González-Suárez, Inés, Rodríguez de Antonio, Luis A., Masjuan, Jaime, Costa-Frossard, Lucienne, Villar, Luisa M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Female Humans Immunologic Factors - pharmacology Immunologic Factors - therapeutic use Leukocytes - drug effects Leukocytes - metabolism Longitudinal Studies Male Middle Aged Multiple Sclerosis, Chronic Progressive - blood Multiple Sclerosis, Chronic Progressive - drug therapy Prospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!